BPI fold containing family B member 3Genealiases: C20orf185 · LPLUNC3 · RYA3
Q-omics provides the consensus-scored BPIFB3 profile across patient tissues and cancer cell-line models. BPIFB3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, BPIFB3 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, BPIFB3 RNA expression shows 6,697 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where BPIFB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFB3 survival associations across molecular data types. BPIFB3 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFB3 RNA expression–survival associations across cancer types. High BPIFB3 expression shows unfavorable associations in STAD, BLCA, THCA, LGG and ACC, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for BPIFB3 RNA expression.
This table summarizes BPIFB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BPIFB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFB3 shows lower tumor expression in THCA and higher tumor expression in LUSC and LUAD. The THCA box plot shows higher BPIFB3 RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p = .005).
This table shows molecular features associated with BPIFB3 in patient tissues and cancer cell lines. In patient samples, BPIFB3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
